New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?

La Revue de médecine interne
S HalimiM Muller

Abstract

Treatment of type 2 diabetes (T2DM) is based on lifestyle changes and oral antidiabetic agents or insulin. The UKPDS study has confirmed metformin (Met) as the initial monotherapy. Accordingly, Met is widely regarded as the first drug of choice for most patients with T2DM. Safety and efficacy of sulphonylureas (SU) have been confirmed by several clinical trials. Recently, thiazolidinediones (TZD) have addressed some aspects of insulin-resistance that characterized several T2DM patients. However, SU and TZD are associated with various side effects that limit their use in many patients. New agents have been recently developed which potentiate the activity of the incretin (GLP1). GLP1, a gut hormone secreted in response to meal ingestion, is rapidly degraded by dipeptidylpeptidase-4 (DPP-4). GLP1 enhances insulin secretion and inhibits glucagon secretion in a glucose-dependent manner, delays gastric emptying and, in animal studies, preserves beta-cell mass by reducing apoptosis and stimulates of beta-cell proliferation. GLP1 levels are abnormally low in T2DM patients. Two classes of agents based on GLP1 have been launched: DPP-4 inhibitors and DPP-4 resistant GLP1 analogues. Randomized studies confirmed their efficacy to improve g...Continue Reading

References

Jul 27, 2001·Diabetes Technology & Therapeutics·N F Wiernsperger
Mar 1, 2003·Diabetes Care·Paul HoganUNKNOWN American Diabetes Association
Jan 11, 2005·La Revue de médecine interne·S Halimi
Sep 15, 2005·Archives of Ophthalmology·Michael Colucciello
Oct 11, 2005·Lancet·Hannele Yki-Järvinen
Oct 19, 2005·Annals of Internal Medicine·Robert J HeineUNKNOWN GWAA Study Group
Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group
Feb 3, 2007·The New England Journal of Medicine·David M Nathan
Mar 22, 2007·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·S DejagerA Schweizer
May 4, 2007·The Journal of Clinical Investigation·Marc L Reitman, Eric E Schadt
May 15, 2007·Gastroenterology·Laurie L Baggio, Daniel J Drucker
May 19, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·A SchweizerS Dejager
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski
Jul 12, 2007·JAMA : the Journal of the American Medical Association·Renee E AmoriAnastassios G Pittas
Sep 13, 2007·JAMA : the Journal of the American Medical Association·A Michael LincoffSteven E Nissen

❮ Previous
Next ❯

Citations

Jan 18, 2011·Diabetes & Metabolism·M BouchouchaR Cohen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

© 2022 Meta ULC. All rights reserved